DMT310-009 Topical in the Treatment of Acne Vulgaris

Launched by DERMATA THERAPEUTICS · Oct 13, 2023

Keywords

ClinConnect Summary

This clinical trial, called DMT310-009, is studying a new treatment for acne called DMT310, which is a topical powder that you mix with a liquid before applying. The goal is to see how safe and effective this treatment is for people with moderate to severe acne on their faces. The trial is currently looking for participants of all genders, aged 9 and older, who have a specific type of acne that includes both inflamed and non-inflamed lesions on their face.

To be eligible for this study, participants must be either male or non-pregnant females and should be willing to follow the instructions for using the treatment. Importantly, those who are pregnant or planning to become pregnant, or who are currently using other medications for their acne, cannot join the trial. If you decide to participate, you can expect to apply the treatment as directed and attend follow-up visits to monitor your progress. This trial aims to help find new options for treating acne, which can be a challenging condition for many people.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient sex at birth, male or non-pregnant female at least 9 years of age
• * Clinical diagnosis of moderate to severe acne vulgaris as determined by:
• • Investigator's Global Assessment (IGA) at Randomization; Patient has at least 20 inflammatory lesions and at least 20 noninflammatory lesions on the face
• • Patient is willing to apply the Investigational Product as directed
• • Patient is willing and able to comply with the protocol
• Exclusion Criteria:
• • Patient is pregnant or planning to become pregnant
• • Patient is taking a topical therapy on the face which may affect the patient's acne